Cooper Financial Group grew its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 2.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,052 shares of the healthcare product maker’s stock after purchasing an additional 107 shares during the period. Cooper Financial Group’s holdings in Abbott Laboratories were worth $421,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Signature Resources Capital Management LLC acquired a new stake in Abbott Laboratories during the fourth quarter valued at approximately $29,000. Transcendent Capital Group LLC acquired a new position in Abbott Laboratories during the fourth quarter worth $29,000. Richardson Financial Services Inc. acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at $29,000. Redmont Wealth Advisors LLC bought a new stake in shares of Abbott Laboratories in the 1st quarter worth about $30,000. Finally, True Wealth Design LLC lifted its holdings in Abbott Laboratories by 1,677.8% during the 4th quarter. True Wealth Design LLC now owns 320 shares of the healthcare product maker’s stock valued at $35,000 after purchasing an additional 302 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.
Abbott Laboratories Stock Up 0.3 %
ABT traded up $0.35 on Tuesday, hitting $108.15. 2,110,581 shares of the company were exchanged, compared to its average volume of 6,016,354. The stock’s fifty day moving average is $105.04 and its 200-day moving average is $108.81. Abbott Laboratories has a 12 month low of $89.67 and a 12 month high of $121.64. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.11 and a current ratio of 1.68. The company has a market cap of $188.14 billion, a PE ratio of 33.75, a PEG ratio of 2.74 and a beta of 0.72.
Abbott Laboratories Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, August 15th. Shareholders of record on Monday, July 15th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Monday, July 15th. This represents a $2.20 annualized dividend and a yield of 2.03%. Abbott Laboratories’s dividend payout ratio is 68.54%.
Analysts Set New Price Targets
ABT has been the topic of several recent analyst reports. The Goldman Sachs Group assumed coverage on Abbott Laboratories in a report on Thursday, May 30th. They issued a “buy” rating and a $121.00 target price on the stock. Edward Jones cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, July 30th. Royal Bank of Canada reissued an “outperform” rating and set a $125.00 price target on shares of Abbott Laboratories in a research note on Tuesday, June 4th. Barclays boosted their price objective on shares of Abbott Laboratories from $140.00 to $143.00 and gave the stock an “overweight” rating in a research report on Monday, July 29th. Finally, Citigroup lowered their target price on Abbott Laboratories from $128.00 to $119.00 and set a “buy” rating for the company in a research note on Wednesday, May 22nd. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $121.00.
Read Our Latest Report on Abbott Laboratories
Abbott Laboratories Company Profile
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Featured Stories
- Five stocks we like better than Abbott Laboratories
- Golden Cross Stocks: Pattern, Examples and Charts
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- Learn Technical Analysis Skills to Master the Stock Market
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- What Are the FAANG Stocks and Are They Good Investments?
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.